AR060385A1 - Compuestos organicos y sus usos - Google Patents
Compuestos organicos y sus usosInfo
- Publication number
- AR060385A1 AR060385A1 ARP070101481A ARP070101481A AR060385A1 AR 060385 A1 AR060385 A1 AR 060385A1 AR P070101481 A ARP070101481 A AR P070101481A AR P070101481 A ARP070101481 A AR P070101481A AR 060385 A1 AR060385 A1 AR 060385A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- aryl
- amino
- heteroaryl
- cycloalkyl
- Prior art date
Links
- 150000002894 organic compounds Chemical class 0.000 title abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 13
- 125000000217 alkyl group Chemical group 0.000 abstract 11
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 10
- -1 aryl-heteroaryl Chemical group 0.000 abstract 8
- 125000003545 alkoxy group Chemical group 0.000 abstract 4
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 4
- 125000001072 heteroaryl group Chemical group 0.000 abstract 4
- 125000000623 heterocyclic group Chemical group 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 125000005213 alkyl heteroaryl group Chemical group 0.000 abstract 3
- 125000002102 aryl alkyloxo group Chemical group 0.000 abstract 3
- 125000004104 aryloxy group Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 3
- 125000005842 heteroatom Chemical group 0.000 abstract 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 2
- 125000003342 alkenyl group Chemical group 0.000 abstract 2
- 125000003282 alkyl amino group Chemical group 0.000 abstract 2
- 125000002877 alkyl aryl group Chemical group 0.000 abstract 2
- 125000000304 alkynyl group Chemical group 0.000 abstract 2
- 125000001769 aryl amino group Chemical group 0.000 abstract 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 2
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 150000002367 halogens Chemical group 0.000 abstract 2
- 125000004446 heteroarylalkyl group Chemical group 0.000 abstract 2
- 125000004415 heterocyclylalkyl group Chemical group 0.000 abstract 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 2
- 241000711549 Hepacivirus C Species 0.000 abstract 1
- 229930194542 Keto Chemical group 0.000 abstract 1
- 108091005804 Peptidases Proteins 0.000 abstract 1
- 239000004365 Protease Substances 0.000 abstract 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 abstract 1
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 abstract 1
- 125000005422 alkyl sulfonamido group Chemical group 0.000 abstract 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 abstract 1
- 125000005281 alkyl ureido group Chemical group 0.000 abstract 1
- 125000001691 aryl alkyl amino group Chemical group 0.000 abstract 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 abstract 1
- 125000005518 carboxamido group Chemical group 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000000000 cycloalkoxy group Chemical group 0.000 abstract 1
- 125000006310 cycloalkyl amino group Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 150000002148 esters Chemical group 0.000 abstract 1
- 125000004404 heteroalkyl group Chemical group 0.000 abstract 1
- 125000005241 heteroarylamino group Chemical group 0.000 abstract 1
- 125000005553 heteroaryloxy group Chemical group 0.000 abstract 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 1
- 125000005844 heterocyclyloxy group Chemical group 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 125000000468 ketone group Chemical group 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 abstract 1
- 125000004001 thioalkyl group Chemical group 0.000 abstract 1
- 125000005000 thioaryl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
- C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente solicitud describe compuestos orgánicos que son utiles para el tratamiento, la prevencion, y/o el alivio de enfermedades humanas. Reivindicacion 1: Un compuesto de la formula 1 y sales farmacéuticamente aceptables de los mismos y sus estereoisomeros; en donde: x es 0 o 1; y es 0 o 1; R1, R2, R4, R5, R6, W, R13 y V, se seleccionan cada uno independientemente, a partir de hidrogeno, o a partir del grupo que consiste en alquilo, aralquilo, heteroalquilo, heterocicloalquilo, heteroarilo, aril-heteroarilo, alquil-heteroarilo, cicloalquilo, alquiloxilo, aralquiloxilo, ariloxilo, heteroariloxilo, heterocicliloxilo, cicloalquiloxilo, mono- y di-alquil-amino, aril-amino, aralquil-amino, heteroaril-amino, cicloalquil-amino, carboxi-alquil-amino, aril-alquiloxilo, y heterociclilamino; cada uno de los cuales, además puede estar independientemente sustituido una o más veces con X1 y X2 en donde X1 es alquilo, alquenilo, alquinilo, cicloalquilo, cicloalquil-alquilo, heterociclilo, heterociclilalquilo, arilo, alquilarilo, arilalquilo, aril-heteroarilo, heteroarilo, heterociclil-amino, alquil-heteroarilo, o heteroaril-alquilo; en donde X1 puede estar sustituido independientemente con una o más fracciones de X2, el cual puede ser el mismo o diferente y se seleccionan de manera independiente; en donde X2 es hidroxilo, alquilo, arilo, alcoxilo, ariloxilo, tio, tioalquilo, tioarilo, amino, alquil-amino, aril-amino, alquil-sulfonilo, aril-sulfonilo, alquil- sulfonamido, aril-suIfonamido, carboxilo, carbaIcoxilo, carboxamido, alcoxi-carbonil-amino, alquil-ureido, halogeno, ciano, queto, éster, o nitro; en donde cada uno de los alquilos, alcoxilo, y arilos mencionados, pueden estar insustituidos o de manera opcional, sustituidos independientemente con una o más fracciones, las cuales pueden ser las mismas o diferentes, y son seleccionadas independientemente a partir de alquilo, alquenilo, alquinilo, cicloalquilo, cicloalquil-alquilo, heterociclilo, heterociclil-alquilo, arilo, alquil-arilo, aril-alquilo, aril-heteroarilo, heteroarilo, heterociclil-amino, alquil-heteroarilo, y heteroaril-alquilo; W también se selecciona a partir del grupo que consiste en C(O)OH, C(O)OR24, C(O)- amina, C(O)-C(O)CH, C(=N-O-R24)-C(O)-amina, C(O)N(H)S(O)2R24, C(O)-C(O)-amina, CON(H)SO2, y C(O)[C(O)]a-heterociclo, en donde el heterociclo puede estar sustituido o insustituido, en donde a es 0 o 1, en donde cada R24 se selecciona de manera independiente a partir del grupo que consiste en H, halogeno, COOH, amino, C(O)NH2, alquilo C1-4, cicloalquilo C3-6-alquilo C0-4, cicloalquilo C3-6-alcoxilo C0-4, mono- y di-alquil-amino C1-4, arilo, ariloxilo, aralquilo, aralquiloxilo, heterociclo- alquilo C0-4 y heterociclo-alcoxilo C0-4; V también se selecciona a partir del grupo que consiste en -Q1- Q2, en donde Q1 está ausente C(O), N(H), N(alquilo C1-4), C=N(CN), C=N(SO2CH3), o C=N-COH, y Q2 es H o se selecciona a partir del grupo que consiste en alquilo C1-4, O-alquiloC1-4, NH2 N(H)-alquilo C1-4N(alquilo C1-4)2, SO2-arilo, SO2-alquilo C1-4, cicloalquilo C3-6-alquilo C0-4, arilo, heteroarilo, y heterociclo, cada uno de los cuales puede estar independientemente sustituido una o más veces con un átomo de halogeno, alquilo C1-4, alquilo C1-4 sustituido por uno o más átomos de halogeno, o cicloalquilo C3-6; R3, R8, R9, R10, R11 y R13 se seleccionan, cada uno independientemente, a partir del grupo que consiste en H, alquilo C1- 4 y cicloalquilo C3-6-alquilo C0-4; y R12 se selecciona a partir del grupo que consiste en H, alquilo C1-4, y cicloalquilo C3-6-alquilo C0-4 y arilo; o R1 y R2 pueden formar juntos un anillo de 3, 4, 5, 6, o 7 miembros, que es aromático o no aromático y puede contener uno o más heteroátomos, en donde el anillo además puede estar sustituido una o más veces; o R11 y V pueden formar juntos un anillo de 3, 4, 5, 6, o 7 miembros, que es aromático o no aromático y puede contener uno o más heteroátomos adicionales en donde el anillo además puede estar sustituido una o más veces; o en donde x e y son 0, R6 y V forman juntos un anillo de 3, 4, 5, 6, o 7 miembros, que es aromático o no aromático, y puede contener uno o más heteroátomos adicionales, en donde el anillo además puede estar sustituido una o más veces. Reivindicacion 65: El compuesto de la reivindicacion 64, en donde el compuesto es un inhibidor de la proteasa NS3-4A del virus de hepatitis C.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US79157806P | 2006-04-11 | 2006-04-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR060385A1 true AR060385A1 (es) | 2008-06-11 |
Family
ID=38516151
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070101481A AR060385A1 (es) | 2006-04-11 | 2007-04-09 | Compuestos organicos y sus usos |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20070265281A1 (es) |
| EP (1) | EP2007788A2 (es) |
| JP (1) | JP2009536158A (es) |
| KR (1) | KR20080104366A (es) |
| CN (1) | CN101421292A (es) |
| AR (1) | AR060385A1 (es) |
| AU (1) | AU2007238253A1 (es) |
| BR (1) | BRPI0710183A2 (es) |
| CA (1) | CA2648678A1 (es) |
| CL (1) | CL2007001004A1 (es) |
| MX (1) | MX2008013125A (es) |
| PE (1) | PE20080355A1 (es) |
| RU (1) | RU2008144294A (es) |
| TW (1) | TW200815479A (es) |
| WO (1) | WO2007121125A2 (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2007789B1 (en) | 2006-04-11 | 2015-05-20 | Novartis AG | Spirocyclic HCV/HIV inhibitors and their uses |
| AR068756A1 (es) * | 2007-10-10 | 2009-12-02 | Novartis Ag | Compuestos peptidicos, formulacion farmaceutica y sus usos como moduladores del virus de la hepatitis c |
| RU2490272C2 (ru) | 2008-02-04 | 2013-08-20 | Айденикс Фармасьютикалз, Инк. | Макроциклические ингибиторы серинпротеазы |
| EP2279011B1 (en) | 2008-04-30 | 2017-10-25 | Siemens Medical Solutions USA, Inc. | Substrate based pet imaging agents |
| WO2010118078A1 (en) | 2009-04-08 | 2010-10-14 | Idenix Pharmaceuticals, Inc. | Macrocyclic serine protease inhibitors |
| US8512690B2 (en) | 2009-04-10 | 2013-08-20 | Novartis Ag | Derivatised proline containing peptide compounds as protease inhibitors |
| TW201117812A (en) | 2009-08-05 | 2011-06-01 | Idenix Pharmaceuticals Inc | Macrocyclic serine protease inhibitors |
| AU2011283008A1 (en) * | 2010-07-30 | 2013-01-24 | Merck Sharp & Dohme Corp. | Inhibition of CYP3A drug metabolism |
| US9353100B2 (en) | 2011-02-10 | 2016-05-31 | Idenix Pharmaceuticals Llc | Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections |
| US20140142337A1 (en) * | 2011-06-21 | 2014-05-22 | Mitsubishi Gas Chemical Company, Inc. | 1-amino-2-vinylcyclopropane carboxylic acid amide and salt thereof, and method for producing same |
| CN108658826B (zh) * | 2018-06-02 | 2020-05-12 | 上海三牧化工技术有限公司 | 一种制备维达列汀的方法 |
| WO2023122587A2 (en) * | 2021-12-20 | 2023-06-29 | The Board Of Regents Of The University Of Texas System | Tripeptide linkers and methods of use thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20030081297A (ko) * | 2000-07-21 | 2003-10-17 | 쉐링 코포레이션 | Ｃ형 간염 바이러스의 ｎｓ3-세린 프로테아제억제제로서의 신규한 펩티드 |
| DK1385870T3 (da) * | 2000-07-21 | 2010-07-05 | Schering Corp | Peptider som inhibitorer af NS3-serinprotease fra hepatitis C-virus |
| US6894072B2 (en) * | 2002-01-23 | 2005-05-17 | Schering Corporation | Compounds as NS3-serine protease inhibitors of hepatitis C virus |
| CA2370396A1 (en) * | 2002-02-01 | 2003-08-01 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis c inhibitor tri-peptides |
| US6642204B2 (en) * | 2002-02-01 | 2003-11-04 | Boehringer Ingelheim International Gmbh | Hepatitis C inhibitor tri-peptides |
| JP4874227B2 (ja) * | 2004-02-27 | 2012-02-15 | シェーリング コーポレイション | Ｃ型肝炎ウイルスのｎｓ３セリンプロテアーゼインヒビターとしての環状ｐ４’ｓを有する新規ケトアミド |
| CN1946691A (zh) * | 2004-02-27 | 2007-04-11 | 先灵公司 | 作为丙型肝炎病毒ns3丝氨酸蛋白酶抑制剂的化合物 |
| EP1737821B1 (en) * | 2004-02-27 | 2009-08-05 | Schering Corporation | 3,4-(cyclopentyl)-fused proline compounds as inhibitors of hepatitis c virus ns3 serine protease |
| US7635694B2 (en) * | 2004-02-27 | 2009-12-22 | Schering Corporation | Cyclobutenedione-containing compounds as inhibitors of hepatitis C virus NS3 serine protease |
| AR049635A1 (es) * | 2004-05-06 | 2006-08-23 | Schering Corp | (1r,2s,5s)-n-((1s)-3-amino-1-(ciclobutilmetil)-2,3-dioxopropil)-3-((2s)-2-((((1,1-dimetiletil)amino)carbonil)amino)-3,3-dimetil-1-oxobutil)-6,6-dimetil-3-azabiciclo(3.1.0)hexan-2-carboxamida como inhibidor de la ns3/ns4a serina proteasa del virus de la hepatitis c |
| ES2328596T3 (es) * | 2004-05-20 | 2009-11-16 | Schering Corporation | Prolinas sustituidas como inhibidores de la serina proteasa del virus ns3 de la hepatitis c. |
| ATE513844T1 (de) * | 2004-08-27 | 2011-07-15 | Schering Corp | Acylsulfonamidverbindungen als inhibitoren der ns3-serinprotease des hepatitis-c-virus |
| US20060281689A1 (en) * | 2005-06-02 | 2006-12-14 | Schering Corporation | Method for modulating activity of HCV protease through use of a novel HCV protease inhibitor to reduce duration of treatment period |
-
2007
- 2007-04-09 AR ARP070101481A patent/AR060385A1/es not_active Application Discontinuation
- 2007-04-09 MX MX2008013125A patent/MX2008013125A/es not_active Application Discontinuation
- 2007-04-09 BR BRPI0710183-0A patent/BRPI0710183A2/pt not_active IP Right Cessation
- 2007-04-09 AU AU2007238253A patent/AU2007238253A1/en not_active Abandoned
- 2007-04-09 EP EP07781535A patent/EP2007788A2/en not_active Withdrawn
- 2007-04-09 KR KR1020087024898A patent/KR20080104366A/ko not_active Ceased
- 2007-04-09 US US11/697,901 patent/US20070265281A1/en not_active Abandoned
- 2007-04-09 JP JP2009505556A patent/JP2009536158A/ja active Pending
- 2007-04-09 CA CA002648678A patent/CA2648678A1/en not_active Abandoned
- 2007-04-09 RU RU2008144294/04A patent/RU2008144294A/ru not_active Application Discontinuation
- 2007-04-09 WO PCT/US2007/066205 patent/WO2007121125A2/en not_active Ceased
- 2007-04-09 CN CNA2007800129167A patent/CN101421292A/zh active Pending
- 2007-04-10 PE PE2007000434A patent/PE20080355A1/es not_active Application Discontinuation
- 2007-04-10 CL CL200701004A patent/CL2007001004A1/es unknown
- 2007-04-10 TW TW096112551A patent/TW200815479A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2009536158A (ja) | 2009-10-08 |
| WO2007121125A3 (en) | 2008-04-24 |
| KR20080104366A (ko) | 2008-12-02 |
| CL2007001004A1 (es) | 2008-03-14 |
| CN101421292A (zh) | 2009-04-29 |
| AU2007238253A1 (en) | 2007-10-25 |
| BRPI0710183A2 (pt) | 2011-08-09 |
| RU2008144294A (ru) | 2010-05-20 |
| MX2008013125A (es) | 2008-10-21 |
| US20070265281A1 (en) | 2007-11-15 |
| PE20080355A1 (es) | 2008-06-02 |
| WO2007121125A2 (en) | 2007-10-25 |
| CA2648678A1 (en) | 2007-10-25 |
| TW200815479A (en) | 2008-04-01 |
| EP2007788A2 (en) | 2008-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR060385A1 (es) | Compuestos organicos y sus usos | |
| AR060405A1 (es) | Compuestos organicos y sus usos en tratamientos de infeccion por el virus de hepatitis c | |
| AR061486A1 (es) | Derivados de 2-pirazinacarboxamida | |
| AR061581A1 (es) | Compuestos de pirro[1,2-b]piridazinona,composiciones farmaceuticas que los contienen y usos para tratar hepatitis c. | |
| AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
| CO5570668A2 (es) | Derivados triciclicos sustituidos de himbacina que son antagonistas del receptor de trombina y composiciones farmaceuticas que los contienen | |
| AR066014A1 (es) | Difenil- dihidro -imidazopiridinonas. composiciones farmaceuticas y usos. | |
| AR055592A1 (es) | Derivados de 2-amino-5-cicloalquil-hidantoina como moduladores y/o inhibidores de la beta-secretasa(bace) | |
| ECSP055815A (es) | Composición para el tratamiento de la infección por virus flaviviridae | |
| CO5590957A2 (es) | Amino-1,3,5-triazinas sustituidas en n con radicales biciclicos quirales, procedimiento para su preparacion, composiciones de las mismas y su uso como herbicidas y reguladores del crecimiento de las plantas | |
| HUP0401784A2 (hu) | Heterobiciklikus szerkezetû virális polimeráz inhibitorok, eljárás az elõállításukra, köztitermékek és ezeket tartalmazó gyógyszerkészítmények | |
| AR020851A2 (es) | Compuestos macrolidos, composiciones y su uso para la preparacion de medicamentos | |
| CO5700774A2 (es) | Derivados de triazol como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa-1 | |
| AR046845A1 (es) | Derivados de 1h-imidazo[4,5-c]quinolina para tratamiento de enfermedades dependientes de las proteino-quinasas | |
| AR047056A1 (es) | Derivados de pirimidinas condensadas. composiciones farmacéuticas | |
| AR046186A1 (es) | Compuestos derivados de 1,3,8-triaza-espiro[4.5]decan-4-ona | |
| PE20081471A1 (es) | Derivados de heteroarilnitrilo como inhibidores de cisteina proteasa | |
| ECSP099324A (es) | Nuevos derivados de aminopirimidina como inhibidores de plk1 | |
| PE20061106A1 (es) | Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida | |
| AR043700A1 (es) | Derivados de 3-substituida-4-pirimidona | |
| AR042941A1 (es) | Derivados de tiazol, su preparacion, composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos inhibidores de la proteina-1 de adhesion vascular (vap-1) | |
| AR062110A1 (es) | Derivado de anillo fusionado de espiroquetas y su uso como farmaco antidiabetico | |
| AR058885A1 (es) | Compuestos de piperidina 3,5-sustituidos | |
| AR055283A1 (es) | Inhibidores de cisteinproteasa de catepsina | |
| PE20071064A1 (es) | Derivados de pirrolonaftiridinonas como antibacterianos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |